Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

Steven H. Stein currently works at Repare Therapeutics, Inc., as Director from 2024, Incyte Corp., as Chief Medical Officer & Executive Vice President from 2016, the University of Pennsylvania, as ...

Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., (GLOBE ...

“BioNTech’s robust financial position empowers us to pursue our strategic goal of evolving into a leading biotech company with multiple oncology products by 2030.” Cost of sales was 83.8 ...

Novartis' strategy to focus largely in areas of unmet medical need should strengthen the firm's pricing power. The firm's key areas of innovation focus on oncology, immunology, neurology ...

So, Kisqali (ribociclib) is one of the key medicines in Novartis' oncology portfolio that has received approval from the FDA and other agencies. It is for the treatment of people with breast ...

Novartis announced that it has acquired Mariana Oncology, a biotech specializing in developing radioligand therapies (RLTs) for cancer treatment. According to the company, the acquisition is expected ...

Novartis is adding on to its capabilities in radiopharmaceuticals through a deal to acquire Mariana Oncology, a startup with a drug pipeline and technologies that diversify the pharmaceutical ...

Novartis (NYSE:NVS) has agreed to acquire cancer drugmaker Mariana Oncology for an upfront payment of $1B and an additional $750M in milestone payments. The transaction, subject to customary ...